Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 8/20 | 0.70 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.68 |
| ▸ | KDR | P35968 | 6/20 | 0.68 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.68 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.68 |
| ▸ | PIM1 | P11309 | 2/20 | 0.58 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.58 |
| ▸ | KIT | P10721 | 3/20 | 0.55 |
| ▸ | FLT3 | P36888 | 3/20 | 0.54 |
| ▸ | CSF1R | P07333 | 1/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.54 |
| ▸ | FLT1 | P17948 | 1/20 | 0.54 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.50 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.49 |
| ▸ | AKT2 | P31751 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4174939 | 1.00 | CHEK1 (0.70) | CHEK1PDGFRBKDRFGFR1TLK2 | |
| SCHEMBL4165999 | 0.93 | CHEK1 (0.78) | CHEK1PDGFRBKDRFGFR1TLK2 | |
| SCHEMBL4166006 | 0.93 | CHEK1 (0.78) | CHEK1PDGFRBKDRFGFR1TLK2 | |
| SCHEMBL4018201 | 0.93 | KDR (0.69) | CHEK1PDGFRBKDRFGFR1TLK2 | |
| SCHEMBL4018205 | 0.93 | KDR (0.69) | CHEK1PDGFRBKDRFGFR1TLK2 | |
| SCHEMBL4017088 | 0.87 | CHEK1 (0.55) | CHEK1PDGFRBKDRFGFR1TLK2 | |
| SCHEMBL4017090 | 0.87 | CHEK1 (0.55) | CHEK1PDGFRBKDRFGFR1TLK2 | |
| SCHEMBL4013804 | 0.83 | CHEK1 (0.70) | CHEK1PDGFRBKDRFGFR1TLK2 | |
| SCHEMBL4013806 | 0.83 | CHEK1 (0.70) | CHEK1PDGFRBKDRFGFR1TLK2 | |
| SCHEMBL4164470 | 0.82 | KDR (0.65) | CHEK1PDGFRBKDRFGFR1TLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009085040-A1 | PROTEIN KINASE INHIBITORS | DCB-USA LLC (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090163494-A1 | PROTEIN KINASE INHIBITORS | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163494-A1 | PROTEIN KINASE INHIBITORS | BRAF, MAP3K20, SELENOI | CHEK1 120/4885PDGFRB 2877/4885KDR 2756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.